What is an informed consent form (ICF)?

The Informed Consent Form (ICF) describes the study and how data collected may be shared for study purposes. By signing this form, you are agreeing to participate in the study. Please read the form carefully and, if there is something you do not understand, ask the study doctor or a study team member.

Questions?

To speak to a study representative, contact the SPARKLER Study toll-free at: **866-974-3979**.

Hours of Operation:
M – F 9:00am – 5:00pm, EST
For more information visit:
www.FILSPARI-registry.com.

v1.0_30May2024

SPARKLERStudy

An Observational Study for Patients Treated with FILSPARI

Patient Information Pamphlet

What is the SPARKLER Study?

This is an observational research study for adults who have been identified as being treated with the drug FILSPARI® (sparsentan), which has been approved by the Food and Drug Administration (FDA) to reduce levels of protein in the urine (proteinuria) in adults with a kidney disease called primary immunoglobulin A nephropathy (IgAN), and who are at risk of their disease progressing quickly.

The SPARKLER Study is sponsored by Travere Therapeutics, Inc which is responsible for the initiation and financing of the study. Travere Therapeutics has contracted United BioSource, LLC (UBC) to manage the day-to-day activities of the study.

The purpose of this study is to collect any potential liver-related problems that you may experience while taking FILSPARI.

The information that is collected from this observational study will assist in assessing whether FILSPARI may cause Drug-Induced Liver Injury (DILI). It is not known whether FILSPARI causes DILI, which is why it's important to collect the data in this observational study to help us understand more about whether patients are more likely to experience these liver events.

An observational research study means participants will continue to receive care as decided by their healthcare providers. Participation in this study will not change treatment or medical care in any way.

Who can participate in the study?

To participate in this study, participants must:

- Be at least 18 years old
- Plan to begin FILSPARI treatment or have started FILSPARI treatment within the past 6 weeks
- Able to sign an Informed Consent Form (ICF)

What will participation involve?

Participation will last for approximately 2 years. Your doctor will continue to make treatment decisions for you and conduct standard of care visits. There will be no additional visits beyond those scheduled as part of routine care.

Participants will receive a brief phone call every 3 months during the study to check for any changes in health.

Why participate in this study?

Participants may help others by increasing the understanding of the potential for drug induced liver injury in patients treated with FILSPARI. Participation may benefit patients in the future by providing new safety and medical information.

Your participation in the study is strictly voluntary. You may withdraw from the study at any time.

Will my privacy be protected?

The doctor and their staff will respect the privacy of all participants who take part. All personal medical information will be kept strictly confidential. Further information about privacy, is provided in the Informed Consent Form.